Adverse events
|
Severity, n (%)
|
---|
All grades
|
Grade 1
|
Grade 2
|
Grade 3
|
---|
Hematologic
|
PB regimen (n = 51)
|
Anemia
|
30 (58.8)
|
18 (35.3)
|
9 (17.6)
|
3 (5.9)
|
Leukopenia
|
21 (41.2)
|
10 (19.6)
|
8 (15.7)
|
3 (5.9)
|
Neutropenia
|
19 (37.3)
|
2 (3.9)
|
9 (17.6)
|
8 (15.7)
|
Eribulin maintenance therapy (n = 45)
|
Anemia
|
26 (57.8)
|
21 (46.7)
|
4 (8.9)
|
1 (2.2)
|
Leukopenia
|
24 (53.3)
|
9 (20.0)
|
10 (22.2)
|
5 (11.1)
|
Neutropenia
|
23 (51.1)
|
2 (4.4)
|
12 (26.7)
|
9 (20.0)
|
Nonhematologic
|
PB regimen (n = 51)
|
Alopecia
|
51 (100.0)
|
2 (3.9)
|
49 (96.1)
|
–
|
Peripheral sensory neuropathy
|
37 (72.5)
|
28 (54.9)
|
8 (15.7)
|
1 (2.0)
|
Increased AST
|
15 (29.4)
|
13 (25.5)
|
1 (2.0)
|
1 (2.0)
|
Dysgeusia
|
15 (29.4)
|
15 (29.4)
|
0 (0.0)
|
–
|
Epistaxis
|
15 (29.4)
|
15 (29.4)
|
0 (0.0)
|
0 (0.0)
|
Fatigue
|
12 (23.5)
|
10 (19.6)
|
2 (3.9)
|
0 (0.0)
|
Arthralgia
|
12 (23.5)
|
12 (23.5)
|
0 (0.0)
|
0 (0.0)
|
Rash
|
12 (23.5)
|
12 (23.5)
|
0 (0.0)
|
0 (0.0)
|
Increased ALT
|
10 (19.6)
|
8 (15.7)
|
2 (3.9)
|
0 (0.0)
|
Anorexia
|
10 (19.6)
|
7 (13.7)
|
3 (5.9)
|
0 (0.0)
|
Nail discoloration
|
10 (19.6)
|
10 (19.6)
|
–
|
–
|
Peripheral motor neuropathy
|
9 (17.6)
|
8 (15.7)
|
0 (0.0)
|
0 (0.0)
|
Myalgia
|
8 (15.7)
|
8 (15.7)
|
0 (0.0)
|
0 (0.0)
|
Eribulin maintenance therapy (n = 45)
|
Peripheral sensory neuropathy
|
37 (82.2)
|
18 (40.0)
|
17 (37.8)
|
2 (4.4)
|
Increased AST
|
25 (55.6)
|
21 (46.7)
|
3 (6.7)
|
1 (2.2)
|
Dysgeusia
|
16 (35.6)
|
13 (28.9)
|
3 (6.7)
|
–
|
Increased ALT
|
16 (35.6)
|
14 (31.1)
|
2 (4.4)
|
0 (0.0)
|
Alopecia
|
15 (33.3)
|
8 (17.8)
|
7 (15.6)
|
–
|
Fatigue
|
14 (31.1)
|
10 (22.2)
|
4 (8.9)
|
0 (0.0)
|
Anorexia
|
14 (31.1)
|
11 (24.4)
|
3 (6.7)
|
0 (0.0)
|
Peripheral motor neuropathy
|
13 (28.9)
|
10 (22.2)
|
3 (6.7)
|
0 (0.0)
|
Increased creatinine
|
13 (28.9)
|
12 (26.7)
|
1 (2.2)
|
0 (0.0)
|
Nausea
|
11 (24.4)
|
11 (24.4)
|
0 (0.0)
|
0 (0.0)
|
Arthralgia
|
10 (22.2)
|
9 (20.0)
|
1 (2.2)
|
0 (0.0)
|
Myalgia
|
9 (20.0)
|
7 (15.6)
|
2 (4.4)
|
0 (0.0)
|
Nail loss
|
9 (20.0)
|
4 (8.9)
|
5 (11.1)
|
–
|
Constipation
|
8 (17.8)
|
5 (11.1)
|
3 (6.7)
|
0 (0.0)
|
Epistaxis
|
7 (15.6)
|
7 (15.6)
|
0 (0.0)
|
0 (0.0)
|
Nail discoloration
|
7 (15.6)
|
7 (15.6)
|
–
|
–
|
- CTCAE common terminology criteria for adverse events, PB paclitaxel + bevacizumab, AST aspartate transaminase, ALT alanine transaminase; −, no definition